<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BABYBIG- human botulinum neurotoxin a/b immune globulin injection, powder, lyophilized, for solution </strong><br>CALIFORNIA DEPARTMENT OF PUBLIC HEALTH<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BabyBIG, [<span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Immune Globulin Intravenous (Human)], safely and effectively. See full prescribing information for BabyBIG.<br><br> BabyBIG [<span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Immune Globulin Intravenous (Human) (BIG-IV)]<br> Lyophilized Powder for Reconstitution and Injection<br> Initial U.S. Approval: 2003</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="75%">
<col align="left" valign="top" width="25%">
<tbody class="Headless">
<tr>
<td align="left">Dosage and Administration (<a href="#S2">2</a>)</td>
<td align="left">10/2011</td>
</tr>
<tr>
<td align="left">Warning and Precautions (<a href="#S5">5</a>)</td>
<td align="left">04/2009</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">BabyBIG is an immune globulin intravenous (human) indicated for: </p>
<ul class="Disc"><li>Treatment of infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> caused by toxin types A or B in patients below one year of age (<a href="#S1">1</a>).</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Intravenous use only </span>(<a href="#S2">2</a>) </p>
<ul class="Disc">
<li>Recommended dose is 1.0 mL/kg (50 mg/kg) given as a single intravenous infusion (<a href="#S2">2</a>).</li>
<li>Reconstitute in 2 mL Sterile Water for Injection USP and initiate infusion within 2 hours of reconstitution (<a href="#S2.1">2.1</a>).</li>
<li>Administer BabyBIG through a separate intravenous line (<a href="#S2.3">2.3</a>).</li>
<li>Begin infusion slowly (0.5 mL/kg/h); if no untoward reaction in 15 minutes, increase rate to 1.0 mL/kg/h (<a href="#S2.2">2.2</a>,<a href="#S2.3"> 2.3</a>).</li>
<li>DO NOT EXCEED THE RECOMMENDED DOSE, CONCENTRATION, AND RATE OF INFUSION (<a href="#S2.3">2.3</a>).</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Single-use vial of 100 mg ± 20 mg lyophilized immunoglobulin (<a href="#S3">3</a>)</li>
<li>Reconstitution as directed results in a BabyBIG solution concentration of 50 mg/mL (<a href="#S2.1">2.1</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Prior history of severe reaction to other human immunoglobulin preparations (<a href="#S4">4</a>)</li>
<li>Selective immunoglobulin A deficiency with anti-IgA antibodies (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Assess renal function prior to and following administration (<a href="#S5.1">5.1</a>,<a href="#S5.2"> 5.2</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may occur (<a href="#S5.4">5.4</a>). This risk should be considered when an IgA-deficient patient is to receive subsequent administration of blood products containing IgA after previous treatment with BabyBIG (<a href="#S4">4</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, increased serum viscosity and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in patients receiving immune globulin intravenous (human) (IGIV) therapy (<a href="#S5.6">5.6</a>).</li>
<li>Thrombotic events have occurred in patients receiving IGIV products. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for those at risk of hyperviscosity (<a href="#S5.7">5.7</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> can develop subsequent to IGIV therapy due to enhanced RBC sequestration (<a href="#S5.8">5.8</a>).</li>
<li>IGIV recipients should be monitored for pulmonary adverse reactions, such as Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>) (<a href="#S5.9">5.9</a>).</li>
<li><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> syndrome (AMS) has been reported with other IGIV treatment, especially with high doses or rapid infusion (<a href="#S5.5">5.5</a>).</li>
<li>The product is made from human plasma and may contain infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent (<a href="#S5.3">5.3</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reaction occurring in at least 5% of the patients treated with BabyBIG in a controlled clinical study was mild and transient erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of the face or trunk (<a href="#S6.1">6.1</a>). </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact the California Department of Public Health at 1-510-231-7600 and <span class="Underline">http://www.infantbotulism.org/</span> or FDA at 1-800-FDA-1088 or <span class="Underline">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>The passive transfer of antibodies may interfere with the response to live viral vaccines (<a href="#S7">7</a>).</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>For use only in patients below one year of age (<a href="#S8.4">8.4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Administer at minimum concentration and rate of infusion (<a href="#S2.3">2.3</a>)</li>
</ul></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Preparation for Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Treatment of Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Caused by Toxin Type A or B</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Patient Monitoring for Administration</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Renal Adverse Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Transmission of Blood-Borne Infectious Agents</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>, and Serum Viscosity</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Thrombotic Events</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic Anemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">BabyBIG<span class="Sup">®</span>, <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Immune Globulin Intravenous (Human), is indicated for the treatment of infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> caused by toxin type A or B in patients below one year of age.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For Intravenous Use Only</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Preparation for Administration</h2>
<ul class="Disc">
<li>BabyBIG does not contain a preservative. After reconstitution of the lyophilized product, the vial should be entered only once for the purpose of administration, and the infusion should begin within 2 hours of reconstitution.</li>
<li>Remove the tab portion of the vial cap and clean the rubber stopper with 70% alcohol or equivalent.</li>
<li>Reconstitute the lyophilized powder with 2 mL of Sterile Water for Injection USP, to obtain a 50 mg/mL BabyBIG solution. A double-ended transfer needle or large syringe is suitable for adding the water for reconstitution. When using a double-ended transfer needle, insert one end first into the vial of water. The lyophilized powder is supplied in an evacuated vial; therefore, the water should transfer by suction (the jet of water should be aimed to the side of the vial). After the water is transferred into the evacuated vial, the residual vacuum should be released to hasten the dissolution.</li>
<li>Rotate the container gently to wet all the powder. An approximately 30-minute interval should be allowed for dissolving the powder. DO NOT SHAKE THE VIAL, AS THIS WILL CAUSE FOAMING.</li>
<li>Inspect BabyBIG visually for particulate matter and discoloration prior to administration. Infuse the solution only if it is colorless, free of particulate matter, and not turbid [<span class="Italics">see<a href="#S5"> WARNINGS AND PRECAUTIONS (5)</a></span>].</li>
<li>To prevent the transmission of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> viruses or other infectious agents from one person to another, use sterile disposable syringes and needles. Never reuse syringes and needles.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Treatment of Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Caused by Toxin Type A or B</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended total dosage of BabyBIG is 1.0 mL/kg (50 mg/kg), given as a single intravenous infusion as soon as the clinical diagnosis of infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> is made. BabyBIG should be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and in patients judged to be at increased risk of developing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (including, but not limited to, those with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, or who are receiving known nephrotoxic drugs) [<span class="Italics">see<a href="#S5.1"> WARNINGS AND PRECAUTIONS (5.1)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<ul class="Disc">
<li>Do not pre-dilute BabyBIG before infusion.</li>
<li>Begin infusion within 2 hours after reconstitution is complete and conclude within 4 hours of reconstitution, unless infusion is temporarily interrupted for adverse reaction. Monitor vital signs continuously during infusion.</li>
<li>Administer BabyBIG intravenously using low volume tubing and a constant infusion pump (<span class="Italics">i.e.</span>, an IVAC pump or equivalent) through a separate intravenous line. If a separate line is not possible, it may be "piggybacked" into a pre-existing line if that line contains either Sodium Chloride Injection USP, or one of the following dextrose solutions (with or without NaCl added): 2.5% dextrose in water, 5% dextrose in water, 10% dextrose in water, or 20% dextrose in water. If a pre-existing line must be used, do not dilute BabyBIG more than 1:2 with any of the above-named solutions. Admixtures of BabyBIG with any other solutions have not been evaluated. Use an in-line or syringe-tip sterile, disposable filter (18 μm) for the administration of BabyBIG.</li>
<li>In the absence of prospective data allowing identification of the maximum safe dose, concentration, and rate of infusion in these patients, DO NOT EXCEED THE RECOMMENDED DOSE, CONCENTRATION, AND RATE OF INFUSION.</li>
<li style="border-left:1px solid;"><span class="XmChange">Begin infusion slowly. Administer BabyBIG intravenously at 0.5 mL per kg body weight per hour (25 mg/kg/h). If no untoward reactions occur after 15 minutes, the rate may be increased to 1.0 mL/kg/h (50 mg/kg/h). DO NOT EXCEED THIS RATE OF ADMINISTRATION. Monitor the patient closely during and after each rate change [<span class="Italics">see<a href="#S5.1"> WARNINGS AND PRECAUTIONS (5.1)</a></span>]. At the recommended rates, infusion of the indicated dose should take 97.5 minutes total elapsed time.</span></li>
</ul>
<table width="60%">
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Time (minutes)</th>
<th class="Rrule" align="center">Rate of 5% Solution</th>
<th class="Rrule" align="center">mg/kg/hr</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">0-15</td>
<td class="Rrule" align="center">0.5 mL/kg/h</td>
<td class="Rrule" align="center">25</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">15 to end of infusion</td>
<td class="Rrule" align="center">1.0 mL/kg/h</td>
<td class="Rrule" align="center">50</td>
</tr>
</tbody>
</table>
<ul class="Disc"><li>As adverse reactions experienced by patients treated with immune globulin intravenous (human) (IGIV) products have been related to the infusion rate, if the patient develops a minor side effect (<span class="Italics">i.e.</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>), <span class="Underline">slow the rate of infusion</span> or temporarily interrupt the infusion. If <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or a significant <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> occurs, <span class="Underline">discontinue the infusion</span> and administer epinephrine.</li></ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc"><li>100 mg ± 20 mg lyophilized immunoglobulin per single-dose vial</li></ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<ul class="Disc">
<li>As with other immunoglobulin preparations, BabyBIG should not be used in individuals with a prior history of severe reaction to other human immunoglobulin preparations.<span class="Sup">[1-4]</span>
</li>
<li>Individuals with selective immunoglobulin A deficiency have the potential for developing antibodies to immunoglobulin A and could have <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to the subsequent administration of blood products that contain immunoglobulin A.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">Only administer BabyBIG as an intravenous infusion, since other routes of administration have not been evaluated. Do not use BabyBIG if the reconstituted solution is turbid [<span class="Italics">see<a href="#S2.1"> DOSAGE AND ADMINISTRATION (2.1)</a></span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Patient Monitoring for Administration</h2>
<ul class="Disc">
<li>Patients should be well hydrated prior to the initiation of the BabyBIG infusion.</li>
<li>Assess renal function, including the measurement of blood urea nitrogen (BUN) or serum creatinine prior to the initial infusion of BabyBIG<span class="Italics"> [see<a href="#S2"> DOSAGE AND ADMINISTRATION (2)</a></span>]. Periodic monitoring of renal function tests and urine output is particularly important in patients judged to have a potential risk for developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.<span class="Sup">[1-4] </span>Increases in serum creatinine and BUN have been observed as soon as one to two days following treatment with other IGIV products.</li>
<li>During administration, monitor the patient's vital signs continuously and observe the patient carefully for any associated symptoms.</li>
<li>DO NOT EXCEED THE RECOMMENDED INFUSION RATE of 1 mL/kg/hour (50 mg/kg/h), and follow the infusion schedule closely [<span class="Italics">see<a href="#S2.3"> DOSAGE AND ADMINISTRATION (2.3)</a></span>]. If a patient develops an infusion reaction, slow the rate of infusion immediately or temporarily interrupt the infusion.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Renal Adverse Reactions</h2>
<p class="First">Other IGIV products have been reported to be associated with renal dysfunction, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.<span class="Sup">[5-6]</span> While these reports of renal dysfunction and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been associated with the use of many licensed IGIV products, those that contained sucrose as a stabilizer and were administered at daily doses of 400 mg/kg or greater have accounted for a disproportionate share of the total number.<span class="Sup">[7]</span> BabyBIG contains sucrose as a stabilizer. Patients predisposed to <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> include those patients with any degree of pre-existing <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="441532" conceptname="Monoclonal paraproteinemia">paraproteinemia</span>, or who are receiving known nephrotoxic drugs. Especially in such patients, BabyBIG should be administered at the minimum concentration available and at the minimum rate of infusion practicable.<span class="Sup">[1]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Transmission of Blood-Borne Infectious Agents</h2>
<p class="First">BabyBIG is made from human plasma and, like other plasma products, carries the possibility for transmission of blood-borne viral agents and, theoretically, the Creutzfeldt-Jakob disease agent. The risk of transmission of recognized blood-borne viruses has been reduced by screening plasma donors for prior exposure to certain viruses, for the presence of certain <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span>, and by the viral inactivation and/or removal properties of the precipitation procedures used for the purification of BabyBIG [see<span class="Italics"><a href="#S11"> DESCRIPTION (11)</a></span>]. Despite these measures, some as yet unrecognized blood-borne infectious agents may not be inactivated by the manufacturing process; therefore, BabyBIG, like any other blood product, should be given only if a benefit is expected [<span class="Italics">see<a href="#S17"> PATIENT COUNSELING INFORMATION (17)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h2>
<ul class="Disc">
<li>Severe reactions, such as <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, although not observed during clinical trials with BabyBIG, are a possibility.<span class="Sup">[8,9]</span> Clinical <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> may occur even when the patient is not known to be sensitive to immune globulin products. A reaction may be related to the rate of infusion; therefore, carefully adhere to the infusion rates as outlined under "<a href="#S2.3">DOSAGE AND ADMINISTRATION (2.3)</a>." If <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">drop in blood pressure</span> occurs, discontinue the infusion and administer epinephrine.<span class="Sup">[1-4]</span>
</li>
<li>Although acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> were not seen in clinical trials with BabyBIG, epinephrine should be available for treatment of acute allergic symptoms [<span class="Italics">see<a href="#S6.1"> ADVERSE REACTIONS (6.1)</a></span>]. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> occurs, discontinue the administration of BabyBIG immediately and give supportive care as needed.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic Meningitis</span> Syndrome</h2>
<p class="First">An <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span> syndrome (AMS) has been reported to occur infrequently in association with IGIV administration.<span class="Sup">[10-13]</span> The syndrome usually begins within several hours to two days following IGIV treatment. It is characterized by symptoms and signs that include the following: severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, painful eye movements, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Cerebrospinal fluid studies are frequently positive with <span class="product-label-link" type="condition" conceptid="4240184" conceptname="Pleocytosis">pleocytosis</span> up to several thousand cells per cubic millimeter, predominately from the granulocytic series, and with elevated protein levels up to several hundred mg/dL. Conduct a thorough neurological examination in patients exhibiting such symptoms and signs to rule out other causes of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.<span class="Sup">[10-13]</span> AMS may occur more frequently in association with high total doses (2 g/kg) of IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.<span class="Sup">[1]</span> AMS was not observed in clinical trials of BabyBIG.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>, and Serum Viscosity</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4284608" conceptname="Hyperproteinemia">Hyperproteinemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, and increased serum viscosity have been observed following administration of IGIV products. It is clinically critical to distinguish true <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> from pseudohyponatremia caused by decreased calculated serum <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, a further increase in serum viscosity and a higher risk of <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>. These adverse events have not been observed with BabyBIG.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Thrombotic Events</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Thrombotic events may occur following IGIV treatment. Patients at risk may include those with a history of <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, multiple cardiovascular risk factors, advanced age, impaired <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span>, <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of immobilization, and/or known or suspected hyperviscosity. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients judged to be at risk of developing thrombotic events, administer BabyBIG at the minimum rate of infusion practicable.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic Anemia</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">IGIV products may contain blood group antibodies, which can act as hemolysins and induce in vivo coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin reaction and, rarely, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span> may develop subsequent to IGIV therapy due to enhanced red blood cell sequestration.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Monitor patients for clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>. If these are present after BabyBIG infusion, perform appropriate confirmatory laboratory testing.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Transfusion-Related Acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>)</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Non-cardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> may occur in patients following IGIV treatment.<span class="Sup">[31]</span> <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is characterized by severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, normal left ventricular function, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Symptoms typically occur within 1 to 6 hours following treatment<span class="Italics"> [See<a href="#S17"> PATIENT COUNSELING INFORMATION (17)</a>].</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Monitor patients for pulmonary adverse reactions. If <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient serum.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span> may be managed using oxygen therapy with adequate ventilatory support.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<ul class="Disc">
<li>Serious adverse reactions were not observed in clinical trials using BabyBIG.</li>
<li>The most common adverse reaction observed with BabyBIG treatment during clinical trials (&gt;5%) was <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</li>
<li>Other reactions such as <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> were the most frequent adverse reactions observed during the clinical trials of similarly-prepared human IGIV products<span class="Sup">[21]</span>. The incidence of these reactions was less than 5% of all infusions in BabyBIG clinical trials, and these reactions were most often related to infusion rates.<span class="Sup">[7]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"><span class="Italics">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</span></p>
<p>Two clinical studies of BabyBIG were performed: (1) an adequate and well-controlled study to evaluate safety and efficacy of BabyBIG, which used BabyBIG Lot 1, and (2) an open label study to collect additional safety data and confirm efficacy, which used BabyBIG Lot 2 [<span class="Italics">see<a href="#S14"> Clinical Studies (14)</a></span>].<span class="Sup">[14,15]</span> Different methodologies were used to collect adverse events in the controlled study and open label study. Minor clinical events that were not recorded as adverse events in the controlled study were recorded as adverse events in the open label study.</p>
<p>The only adverse event considered possibly related to BabyBIG administration was a mild, transient erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of the face or trunk. The following table summarizes the occurrence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> by day of study relative to day of treatment for the randomized, controlled clinical trial (RCT) and for the open label study (OLS).</p>
<table width="50%">
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule" align="center" colspan="2" rowspan="3" valign="middle">Day of Study Relative to Treatment</th>
<th class="Lrule Rrule" align="center" colspan="2">RCT</th>
<th class="Rrule" align="center">OLS</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center">Placebo<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>(N=64)</th>
<th class="Rrule" align="center">BabyBIG<br>(N=65)</th>
<th class="Rrule" align="center">BabyBIG<br>(N=293)</th>
</tr>
<tr class="Last"><th class="Lrule Rrule" align="center" colspan="3">n (%)</th></tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Both Gammagard 5% and Gammagard S/D 5% were used as placebo in this study.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Day 0 is the day of treatment.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>In reference to treatment.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" colspan="2">Day -5</td>
<td class="Rrule" align="center">0 (0)</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">6 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day -4</td>
<td class="Rrule" align="center">2 (3)</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">5 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day -3</td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center">4 (6)</td>
<td class="Rrule" align="center">6 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day -2</td>
<td class="Rrule" align="center">5 (8)</td>
<td class="Rrule" align="center">2 (3)</td>
<td class="Rrule" align="center">22 (8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day -1</td>
<td class="Rrule" align="center">4 (6)</td>
<td class="Rrule" align="center">11 (17)</td>
<td class="Rrule" align="center">28 (10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2">Day 0<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">Before<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"> 5 (8)</td>
<td class="Rrule" align="center">9 (14)</td>
<td class="Rrule" align="center">32 (11)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">During &amp; After<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" valign="middle">2 (3)</td>
<td class="Rrule" align="center" valign="middle">9 (14)</td>
<td class="Rrule" align="center" valign="middle">39 (13)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day +1</td>
<td class="Rrule" align="center">2 (3)</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">18 (6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day +2</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">2 (3)</td>
<td class="Rrule" align="center">13 (4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day +3</td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center">0 (0)</td>
<td class="Rrule" align="center">7 (2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2">Day +4</td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">2 (3)</td>
<td class="Rrule" align="center">11 (4)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" colspan="2">Day +5</td>
<td class="Rrule" align="center">2 (3)</td>
<td class="Rrule" align="center">0 (0)</td>
<td class="Rrule" align="center">5 (2)</td>
</tr>
</tbody>
</table>
<p>In the controlled study, when only treatment emergent events are considered, 14% of the BabyBIG-treated patients experienced erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> during or after study infusion. Eight percent of placebo-treated patients also experienced erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in this study. A similar <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is known to occur both in infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> patients who have not received any IGIV products<span class="Sup">[16]</span> and in patients treated with other IGIVs,<span class="Sup">[2,3]</span> making it difficult to ascertain the causality of the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>In the controlled study only, the following adverse events occurred in at least 5% of the patients receiving BabyBIG or placebo:</p>
<table width="60%">
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2" valign="middle">Adverse Event</th>
<th align="center">BabyBIG<br>N=65</th>
<th class="Rrule" align="center">Placebo<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><br>N=64</th>
</tr>
<tr class="Botrule"><th class="Lrule Rrule" align="center" colspan="2">n (%)</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">N (%) of Patients with any AE</th>
<th class="Rrule" align="center" valign="bottom">20 (31)</th>
<th class="Rrule" align="center" valign="bottom">29 (45)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Both Gammagard 5% and Gammagard S/D 5% were used as placebo in this study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> erythematous</td>
<td class="Rrule" align="center">9 (14)</td>
<td class="Rrule" align="center">5 (8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span></td>
<td class="Rrule" align="center">7 (11)</td>
<td class="Rrule" align="center">5 (8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">7 (11)</td>
<td class="Rrule" align="center">9 (14)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center">9 (14)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td class="Rrule" align="center">3 (5)</td>
<td class="Rrule" align="center">9 (14)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">3 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">Respiratory arrest</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">6 (9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Rrule" align="center">1 (2)</td>
<td class="Rrule" align="center">8 (13)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3 (5)</td>
</tr>
</tbody>
</table>
<p>In the open label study only, the following adverse events occurred in at least 5% of the patients:</p>
<table width="60%">
<col align="left" valign="top" width="75%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" valign="middle">Adverse Event</th>
<th class="Rrule" align="center">BabyBIG<br>N=293<br>N (%)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">Patients with Any AE</th>
<th class="Rrule" align="center">285 (97)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Blood pressure increased</span></td>
<td class="Rrule" align="center">221 (75)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Rrule" align="center">190 (65)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></td>
<td class="Rrule" align="center">121 (41)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="261880" conceptname="Atelectasis">Atelectasis</span></td>
<td class="Rrule" align="center">113 (39)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4084392" conceptname="Wheeze - rhonchi">Rhonchi</span></td>
<td class="Rrule" align="center">100 (34)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span></td>
<td class="Rrule" align="center">83 (28)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></td>
<td class="Rrule" align="center">73 (25)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Dermatitis contact</span></td>
<td class="Rrule" align="center">70 (24)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> erythematous</td>
<td class="Rrule" align="center">64 (22)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">58 (20)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td class="Rrule" align="center">54 (18)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Rrule" align="center">54 (18)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oxygen saturation decreased</td>
<td class="Rrule" align="center">51 (17)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">51 (17)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Body temperature decreased</td>
<td class="Rrule" align="center">48 (16)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">Blood pressure decreased</span></td>
<td class="Rrule" align="center">47 (16)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">Cardiac murmur</span></td>
<td class="Rrule" align="center">45 (15)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">39 (13)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span></td>
<td class="Rrule" align="center">37 (13)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></td>
<td class="Rrule" align="center">33 (11)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="73026" conceptname="Abnormal breath sounds">Breath sounds decreased</span></td>
<td class="Rrule" align="center">30 (10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Rrule" align="center">30 (10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td class="Rrule" align="center">29 (10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">Hemoglobin decreased</span></td>
<td class="Rrule" align="center">27 (9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">Stridor</span></td>
<td class="Rrule" align="center">26 (9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infection</span></td>
<td class="Rrule" align="center">23 (8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span></td>
<td class="Rrule" align="center">23 (8)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Injection-site reaction</td>
<td class="Rrule" align="center">21 (7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> NOS</td>
<td class="Rrule" align="center">20 (7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">Peripheral coldness</span></td>
<td class="Rrule" align="center">19 (7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> NOS</td>
<td class="Rrule" align="center">16 (6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td class="Rrule" align="center">16 (6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Injection-site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
<td class="Rrule" align="center">15 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Intubation NOS</td>
<td class="Rrule" align="center">15 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span></td>
<td class="Rrule" align="center">15 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="199075" conceptname="Neurogenic bladder">Neurogenic bladder</span></td>
<td class="Rrule" align="center">15 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">14 (5)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">Tachypnea</span></td>
<td class="Rrule" align="center">14 (5)</td>
</tr>
</tbody>
</table>
<p>Adverse event coding was used in the open label study to distinguish between minor clinical events that required no intervention and more significant events that required intervention. For example, "<span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>" or "decreased blood pressure" was assigned when transient changes in blood pressure were observed, whereas "<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>" or "<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>" was assigned when more prolonged or significant changes were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First"><span class="Italics">Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics">Experience with BabyBIG. </span>No adverse reactions have been identified or reported that are ascribed to the use of BabyBIG during postapproval use. Retrospective publications have shown safety-related information consistent with the safety-related information in the approved product labeling, and no new safety-related information has been presented for BabyBIG.<span class="Sup">[22. 23]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Italics">Experience with Other IGIV Products. </span>Some classes of adverse reactions that have not been reported in BabyBIG clinical studies or postmarketing experience have been observed with the overall post-approval use of other IGIV products, as shown in the following table.</p>
<table width="60%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="70%">
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Respiratory</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">Acute Respiratory Distress Syndrome</span> (<span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">ARDS</span>), <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">Transfusion Related Acute Lung Injury</span> (<span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>), <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="437390" conceptname="Hypoxemia">hypoxemia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Cardiovascular</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Neurological</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Integumentary</span></td>
<td class="Rrule" align="left">Steven-Johnson syndrome, <span class="product-label-link" type="condition" conceptid="4309632" conceptname="Epidermolysis">epidermolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">bullous dermatitis</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Hematologic</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, positive direct antiglobulin (Coombs') test</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">General / Body as a Whole</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Musculoskeletal</span></td>
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Gastrointestinal</span></td>
<td class="Rrule" align="left">Hepatic dysfunction, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<ul class="Disc">
<li>Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving [<span class="Italics">see<a href="#S2"> DOSAGE AND ADMINISTRATION (2)</a></span>].</li>
<li>Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span>, <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, <span class="product-label-link" type="condition" conceptid="4290000" conceptname="Mumps">mumps</span>, and <span class="product-label-link" type="condition" conceptid="4273323" conceptname="Rubella">rubella</span>; THEREFORE, VACCINATION WITH LIVE VIRUS VACCINES SHOULD BE DEFERRED UNTIL APPROXIMATELY THREE OR MORE MONTHS AFTER ADMINISTRATION OF BabyBIG. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.1"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">BabyBIG has been studied for safety and efficacy only in patients below one year of age [<span class="Italics">see<a href="#S6"> ADVERSE REACTIONS (6) </a>and<a href="#S14"> CLINICAL STUDIES (14)</a></span>]. It has not been tested in other populations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Although limited data are available, clinical experience with other immunoglobulin preparations suggests that the major manifestations would be those related to volume overload.<span class="Sup">[1]</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">BabyBIG, <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Immune Globulin Intravenous (Human) (BIG-IV), is a solvent-detergent-treated, sterile, lyophilized powder of <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (IgG), stabilized with 5% sucrose and 1% albumin (human). It contains no preservative. The purified immunoglobulin is derived from pooled adult plasma from persons who were immunized with pentavalent botulinum toxoid and selected for their high titers of neutralizing antibody against botulinum neurotoxins type A and B. All donors were tested and their sera found to be negative for antibodies against the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus and the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C viruses.</p>
<p>The pooled plasma was fractionated by <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> ethanol precipitation of the proteins according to the Cohn/Oncley method, modified to yield a product suitable for intravenous administration.<span class="Sup">[24,25]</span> Several steps in the manufacturing process have been validated for their ability to inactivate or remove viruses that may not have been detected in the Source Plasma.<span class="Sup">[1,26-29]</span></p>
<p>These include Cohn/Oncley fractionation (Fraction I through Supernatant III Filtrate); nanofiltration through one 75-nm and two 35-nm filters; and solvent/detergent viral inactivation. These viral reduction steps have been validated in a series of<span class="Italics"> in vitro </span>experiments for their capacity to inactivate and/or remove Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus type 1 (HIV-1) and the following model viruses: bovine viral <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> virus (BVDV) as a model for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus; mouse <span class="product-label-link" type="condition" conceptid="373189" conceptname="Encephalomyelitis">encephalomyelitis</span> virus (MEMV) as a model for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A virus; and pseudorabies virus (PRV), feline calicivirus (FCV), and Sindbis virus to cover a wide range of physicochemical properties in the model viruses studied. Total mean log<span class="Sub">10</span> reductions range from 4.63 to greater than 16 log<span class="Sub">10</span> as shown in the following table.</p>
<table width="75%">
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="3" valign="middle">Process Step</th>
<th align="center" colspan="6">Mean Reduction Factor (log<span class="Sub">10</span>)</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center" colspan="4">Enveloped Viruses<br>(size in nm)</th>
<th class="Rrule" align="center" colspan="2">Non-Enveloped Viruses<br>(size in nm)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Sindbis<br>(60-70)</th>
<th class="Rrule" align="center">HIV-1<br>(80-100)</th>
<th class="Rrule" align="center">PRV<br>(120-200)</th>
<th class="Rrule" align="center">BVDV<br>(40-60)</th>
<th class="Rrule" align="center">MEMV<br>(22-30)</th>
<th class="Rrule" align="center">FCV<br>(35-39)</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Included hydrophobic chromatography after solvent/detergent treatment.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Cohn/Oncley fractionation</td>
<td class="Rrule" align="center">6.6</td>
<td class="Rrule" align="center">&gt; 9.44</td>
<td class="Rrule" align="center">&gt; 10.37</td>
<td class="Rrule" align="center">6.25</td>
<td class="Rrule" align="center">4.06</td>
<td class="Rrule" align="center">Not done</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nanofiltration</td>
<td class="Rrule" align="center">≥ 6.84</td>
<td class="Rrule" align="center">Not done</td>
<td class="Rrule" align="center">Not done</td>
<td class="Rrule" align="center">≥ 5.4</td>
<td class="Rrule" align="center">Not done</td>
<td class="Rrule" align="center">≥ 6.92</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Solvent/detergent treatment</td>
<td class="Rrule" align="center">Not done</td>
<td class="Rrule" align="center">&gt; 4.51</td>
<td class="Rrule" align="center">&gt; 5.53</td>
<td class="Rrule" align="center">&gt; 4.85</td>
<td class="Rrule" align="center">0.57<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td class="Rrule" align="center">Not done</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Cumulative Reduction Factor (log<span class="Sub">10</span>)</span></td>
<td class="Rrule" align="center" valign="middle">≥ 13.44</td>
<td class="Rrule" align="center" valign="middle">&gt; 13.95</td>
<td class="Rrule" align="center" valign="middle">&gt; 15.9</td>
<td class="Rrule" align="center" valign="middle">≥ 16.5</td>
<td class="Rrule" align="center" valign="middle">4.63</td>
<td class="Rrule" align="center" valign="middle">≥ 6.92</td>
</tr>
</tbody>
</table>
<p>Additional testing performed with bovine parvovirus (as a model for parvovirus B19) showed a mean cumulative reduction factor of greater than 7.34 log<span class="Sub">10</span> for Cohn/Oncley fractionation and solvent/detergent treatment followed by hydrophobic chromatography. A mean cumulative reduction factor of 2.55 log<span class="Sub">10</span> was observed for removal of porcine parvovirus by nanofiltration.</p>
<p>When reconstituted with Sterile Water for Injection USP, each cubic centimeter (milliliter) contains approximately 50 ± 10 mg immunoglobulin, primarily IgG, and trace amounts of IgA and IgM; 50 mg sucrose; 10 mg albumin (human); and approximately 20 × 10<span class="Sup">-3</span> mEq sodium. The reconstituted solution should appear colorless and translucent [<span class="Italics">see<a href="#S2.1"> DOSAGE AND ADMINISTRATION (2.1)</a>,<a href="#S5"> WARNINGS AND PRECAUTIONS (5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">BabyBIG contains IgG antibodies from the immunized donors who contributed to the plasma pool from which the product was derived. The titer of antibodies in the reconstituted product against type A botulinum toxin is at least 15 IU/mL and against type B toxin is at least 4.0 IU/mL. For toxin types A and B, by definition, 1 IU of botulinum antitoxin neutralizes 10,000 intraperitoneal mouse LD<span class="Sub">50</span> of botulinum toxin. The titers of antibody against botulinum neurotoxins C, D, and E have not been determined. In the case of infants who may be exposed to botulinum neurotoxin type A or B, this product is expected to provide the relevant antibodies at levels sufficient to neutralize the expected levels of circulating neurotoxin.<span class="Sup">[14, 30]</span></p>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">BabyBIG contains antibodies specific for botulinum neurotoxin types A and B that bind to and neutralize circulating toxin types A and B in the patient.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Formal studies on pharmacodynamics have not been conducted with BabyBIG.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Traditional pharmacokinetic studies of BabyBIG have not been performed. However, the following table summarizes the mean serum titer of the anti-A component of BabyBIG following administration.</p>
<table width="60%">
<col align="left" valign="top" width="36%">
<col align="center" valign="top" width="32%">
<col align="center" valign="top" width="32%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2" valign="middle">Time</th>
<th class="Rrule" align="center">BabyBIG Lot 1 Anti-A Titer<br>(mean ± S.D.)</th>
<th class="Rrule" align="center">BabyBIG Lot 2 Anti-A Titer<br>(mean ± S.D.)</th>
</tr>
<tr class="Last"><th class="Lrule Rrule" align="center" colspan="2">mIU/mL</th></tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">NOTE: 1 IU of anti-type A or anti-type B antibody neutralizes, by definition, 10<span class="Sup">4</span> mouse LD<span class="Sub">50</span> of botulinum toxin.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Day 1</td>
<td class="Rrule" align="center">Not done</td>
<td class="Rrule" align="center">537.1 ± 213.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 2</td>
<td class="Rrule" align="center">106.7 ± 44.6</td>
<td class="Rrule" align="center">192.2 ± 71.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 4</td>
<td class="Rrule" align="center">90.0 ± 39.2</td>
<td class="Rrule" align="center">155.5 ± 56.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 8</td>
<td class="Rrule" align="center">54.9 ± 22.8</td>
<td class="Rrule" align="center">96.0 ± 33.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 12</td>
<td class="Rrule" align="center">26.0 ± 20.5</td>
<td class="Rrule" align="center">61.4 ± 32.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Week 16</td>
<td class="Rrule" align="center">15.6 ± 10.4</td>
<td class="Rrule" align="center">33.0 ± 22.3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Week 20</td>
<td class="Rrule" align="center">7.6 ± 6.6</td>
<td class="Rrule" align="center">19.3 ± 14.1</td>
</tr>
</tbody>
</table>
<p>The half-life of injected BabyBIG has been shown to be approximately 28 days in infants,<span class="Sup">[14]</span> which is in agreement with existing data for other immunoglobulin preparations.<span class="Sup">[2,14]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Two clinical studies in infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> were performed: (1) an adequate and well-controlled study to evaluate the safety and efficacy of BabyBIG (N=129), and (2) an open label study to collect additional safety data and confirm efficacy (N=293). In the adequate and well-controlled clinical study, BabyBIG, given within the first 3 days of hospital admission to 59 patients with laboratory-confirmed infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>, has been shown to reduce the following:</p>
<table width="75%">
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2"></th>
<th class="Rrule" align="center" colspan="2">Average Length in Weeks</th>
<th class="Rrule" align="center" rowspan="2" valign="middle">p-value</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Placebo<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a><br>N=63</th>
<th class="Rrule" align="center">BabyBIG<br>N=59</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Both Gammagard 5% and Gammagard S/D 5% were used as placebo in this study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Hospital stay</span></td>
<td class="Rrule" align="center">5.7</td>
<td class="Rrule" align="center">2.6</td>
<td class="Rrule" align="center">p&lt;0.0001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Intensive Care Unit stay</span></td>
<td class="Rrule" align="center">3.6</td>
<td class="Rrule" align="center">1.3</td>
<td class="Rrule" align="center">p&lt;0.01</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">Mechanical ventilation</span></td>
<td class="Rrule" align="center">2.4</td>
<td class="Rrule" align="center">0.7</td>
<td class="Rrule" align="center">p&lt;0.05</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Tube-feeding</span></td>
<td class="Rrule" align="center">10.0</td>
<td class="Rrule" align="center">3.6</td>
<td class="Rrule" align="center">p&lt;0.01</td>
</tr>
</tbody>
</table>
<p>Length of hospital stay was also analyzed by patient age in both the adequate and well-controlled study and in an open label study.</p>
<table width="75%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2" valign="middle">Age (days)</th>
<th class="Rrule" align="center" colspan="3">Mean Length of Hospital Stay in Weeks</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Placebo<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a><br>N=63</th>
<th class="Rrule" align="center">BabyBIG (RCT)<br>N=59</th>
<th class="Rrule" align="center">BabyBIG (OLS)<br>N=206</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="4">RCT = randomized clinical trial</td></tr>
<tr class="Last"><td align="left" colspan="4">OLS = open label study</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Both Gammagard 5% and Gammagard S/D 5% were used as placebo in this study.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">0-60</span></td>
<td class="Rrule" align="center">3.8 (N=10)</td>
<td class="Rrule" align="center">2.8 (N=10)</td>
<td class="Rrule" align="center">2.0 (N=46)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">61-120</span></td>
<td class="Rrule" align="center">5.6 (N=29)</td>
<td class="Rrule" align="center">1.9 (N=17)</td>
<td class="Rrule" align="center">2.0 (N=68)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Bold">&gt;120</span></td>
<td class="Rrule" align="center">6.6 (N=24)</td>
<td class="Rrule" align="center">3.0 (N=32)</td>
<td class="Rrule" align="center">1.8 (N=92)</td>
</tr>
</tbody>
</table>
<p>The observed reduction in length of hospital stay was statistically significant (p&lt;0.01) with the exception of the 0 to 60-day age stratum, where small patient numbers limited the statistical power.</p>
<p>Length of hospital stay was analyzed in the adequate and well-controlled study by race (white versus non-white):</p>
<table width="60%">
<col align="left" valign="middle" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2">RACE</th>
<th class="Rrule" align="center" colspan="2">Mean Length of Hospital Stay in Weeks</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Placebo<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>
</th>
<th class="Rrule" align="center">BabyBIG (RCT)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Both Gammagard 5% and Gammagard S/D 5 % were used as placebo in this study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">White</span></td>
<td class="Rrule" align="center">6.3<br>(N=40)</td>
<td class="Rrule" align="center">2.8<br>(N=35)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Non-white</span></td>
<td class="Rrule" align="center">4.6<br>(N=23)</td>
<td class="Rrule" align="center">2.4<br>(N=24)</td>
</tr>
</tbody>
</table>
<p>Length of hospital stay was significantly reduced in both white and non-white patients (p=0.002).</p>
<p>BabyBIG has not been tested for safety and efficacy in adults.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>Cytogam<span class="Sup">®</span>, cytomegalovirus immune globulin intravenous (human) (CMV-IGIV). In: Physician's Desk Reference. 55th Ed. Montvale, New Jersey: Medical Economics Company, Inc.; 2001:1861-1863.</li>
<li>Immune globulin intravenous (human) Iveegam En IGIV. In: Physician's Desk Reference. 55th Ed. Montvale, New Jersey: Medical Economics Company, Inc.; 2001:816-820.</li>
<li>Immune globulin intravenous (human) (IGIV) Gammagard<span class="Sup">®</span> S/D. In: Physician's Desk Reference. 55th Ed. Montvale, New Jersey: Medical Economics Company, Inc.; 2001:812-815.</li>
<li>Immune globulin intravenous (human) Sandoglobulin<span class="Sup">®</span> lyophilized preparation. In: Physician's Desk Reference. 55th Ed. Montvale, New Jersey: Medical Economics Company, Inc.; 2001:2210-2213.</li>
<li>Perazella MA, Cayco AV. <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> and intravenous immune globulin: sucrose <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span> in disguise? Am J Ther 1998; 5:399-403.</li>
<li>Cayco AV, Perazella MA, Hayslett JP. <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span> after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8:1788-1793.</li>
<li>Important Drug Warning ("Dear Doctor") letter. Center for Biologics Evaluation and Research, Food and Drug Administration, 1998.</li>
<li>Denepoux S, et al. Molecular characterization of human IgG monoclonal antibodies specific for major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>. FEBS Lett 2000; 465:39-46.</li>
<li>Burks AW, Sampson HA, Buckley RH. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> after gamma globulin administration in patients with <span class="product-label-link" type="condition" conceptid="440072" conceptname="Hypogammaglobulinemia">hypogammaglobulinemia</span>. Detection of IgE antibodies to IgA. N Engl J Med 1986; 314:560-564.</li>
<li>Sekul EA, Cupler EJ, Dalakas MC. <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121:259-262.</li>
<li>Kato E, Shindo S, Eto Y, et al. Administration of immune globulin associated with <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>. JAMA 1988; 259:3269-3270.</li>
<li>Casteels-Van Daele M, Wijndaele L, Hunninck K. Intravenous immunoglobulin and acute <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>. N Engl J Med 1990; 323:614-615.</li>
<li>Scribner C, Kapit R, Philips E, Rickels N. <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">Aseptic meningitis</span> and intravenous immunoglobulin therapy. Ann Intern Med 1994; 121:305-306.</li>
<li>Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> immune globulin for the treatment of infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>. N Engl J Med 2006; 354:462-471.</li>
<li>Arnon SS. Creation and development of the public service orphan drug Human <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Immune Globulin. Pediatrics 2007; 119:785-789.</li>
<li>Long SS, Gajewski JL, Brown LW, Gilligan PH. Clinical, laboratory, and environmental features of infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> in southeastern Pennsylvania. Pediatrics 1985; 75:935-941.</li>
<li>Schreiner MS, et al. Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>: a review of 12 years' experience at the Children's Hospital of Philadelphia. Pediatrics 1991; 87:159-165.</li>
<li>Wilson R, et al. Clinical characteristics of infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> in the United States: a study of the non-California cases. Pediatr Infect Dis 1982; 1:148-150.</li>
<li>Anderson TD, et al. Airway complications of infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>: ten-year experience with 60 cases. Otolaryngol Head Neck Surg 2002; 126:234-239.</li>
<li>Arnon SS. Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>. In: Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: WB Saunders 2004; 1758-1766.</li>
<li>Snydman DR, Werner BG, Tilney NL, et al. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with cytomegalovirus immune globulin: comparison of the randomized and open-label trials. Transplant Proc 1991; 23:1357-1360.</li>
<li>Tseng-Ong L, Mitchell WG. Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>: 20 years' experience at a single institution. J Child Neurol 2007; 22:1333-1337.</li>
<li>Underwood K, Rubin S, Deakers T, Newth C. Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>: A 30-year experience spanning the introduction of <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span> immune globulin intravenous in the intensive care unit at Childrens Hospital Los Angeles. Pediatrics 2007; 120:e1380-e1385.</li>
<li>Siber GR, Syndman DR. Use of immune globulins in the prevention and treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Curr Clin Top Infect Dis 1992; 12:208-256.</li>
<li>Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobins. Ann Intern Med 1990; 112:278-292.</li>
<li>Bossell J, et al. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/<span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>-associated virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Morb Mortal Wkly Rep 1986; 35:231-233.</li>
<li>Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Trans 1986; 26:210-213.</li>
<li>Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985; 25:516-522.</li>
<li>Edwards CA, Piet MPJ, Chin S, Horowitz B. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987; 52:53-59.</li>
<li>Paton JC, Lawrence AL, Steven IM. Quantitation of<span class="Italics"> Clostridium botulinum </span>organisms and toxin in feces and presence of<span class="Italics"> Clostridium botulinum </span>toxin in the serum of an infant with <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">botulism</span>. J Clin Microbiol 1983; 17:13-15.</li>
<li>Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute <span class="product-label-link" type="condition" conceptid="255674" conceptname="Laceration of lung without open wound into thorax">lung injury</span> after the infusion of IVIG. Transfusion 2001; 41: 264-268.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<ul class="Disc">
<li>NDC 68403-1100-6, 100 mg ± 20 mg lyophilized immunoglobulin single-dose vial individually packaged in a carton, supplied with 2 mL Sterile Water for Injection USP for reconstitution.</li>
<li>Store the vial containing the lyophilized product between 2° and 8°C (35.6° to 46.4°F). Do not store BabyBIG in the reconstituted state.</li>
<li>Use reconstituted BabyBIG within 2 hours.</li>
<li>Do not use beyond expiration date, and dispose unused product in accordance with local requirements.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul class="Disc">
<li>Discuss the risks and benefits of BabyBIG use with the patient's legal guardians, including the possibility of adverse reactions, e.g., <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, as well as <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="443425" conceptname="Transfusion related acute lung injury">TRALI</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> [<span class="Italics">see<a href="#S5"> WARNINGS AND PRECAUTIONS (5)</a></span>].</li>
<li>Inform patient's legal guardians that BabyBIG is made from human plasma and may contain infectious agents that can cause disease. While the risk of transmitting an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been reduced by screening plasma donors for prior exposure, testing donated plasma, and inactivating or removing certain viruses during manufacturing, the patient's guardian should report any symptoms that concern them<span class="Italics"> [see<a href="#S5.3"> WARNINGS AND PRECAUTIONS (5.3)</a>].</span>
</li>
<li>Inform patient's legal guardians that BabyBIG may interfere with immune response to live viral vaccines (e.g., MMR) and instruct them to notify the healthcare provider of this potential interaction when the patient is to receive vaccinations [<span class="Italics">see<a href="#S7"> DRUG INTERACTIONS (7)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">For additional information concerning BabyBIG, contact:</p>
<p>Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Treatment and Prevention Program<br>California Department of Public Health<br>850 Marina Bay Parkway, Room E-361<br>Richmond, California 94804<br>Telephone: 510-231-7600<br>US Govt. License No. 1797</p>
<p>Manufactured by:<br>Baxter Healthcare Corporation<br>Westlake Village, CA 91362, USA<br>US Govt. License No. 140; and</p>
<p>Cangene Corporation<br>Winnipeg, Manitoba, R3T 5Y3, Canada<br>US Govt. License No. 1201</p>
<p>Distributed by:<br>FFF Enterprises<br>Temecula, California 92591, USA</p>
<p>Distributed for:<br>Infant <span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Treatment and Prevention Program<br>California Department of Public Health<br>850 Marina Bay Parkway, Room E-361<br>Richmond, California 94804</p>
<p><span class="Bold">Revised October 2011</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 2 mL Vial Label</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Immune Globulin Intravenous<br>(Human) (BIG-IV)</span></p>
<p><span class="Bold">BabyBIG<span class="Sup">®</span></span></p>
<p><span class="Bold">DO NOT SHAKE VIAL<br>AFTER RECONSTITUTION;<br>AVOID FOAMING.</span><br>See package insert for<br>reconstitution, dosage, and<br>administration. Rx only.<br>Single use container.</p>
<p>Manufactured for:<br>California Department of<br>Public Health<br>by: Baxter Healthcare<br>Corporation and<br>Cangene Corporation</p>
<p>LOT<br>EXP.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9ec59262-35c1-4d8e-8451-a7cfbacb0675&amp;name=babybig-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1 Single Use Vial Carton</span></p>
<p>NDC 68403-1100-6</p>
<p>Rx Only</p>
<p><span class="Bold">100 mg IgG, 100 mg Sucrose<br>20 mg Albumin (Human)<br>Lyophilized<br>Solvent Detergent Treated</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="433687" conceptname="Botulism">Botulism</span> Immune Globulin<br>Intravenous (Human) (BIG-IV)</span></p>
<p><span class="Bold">BabyBIG<span class="Sup">®</span></span></p>
<p>Store between 2°C and 8°C (35.6°F and 46.4°F).</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1 Single Use Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9ec59262-35c1-4d8e-8451-a7cfbacb0675&amp;name=babybig-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BABYBIG 		
					</strong><br><span class="contentTableReg">human botulinum neurotoxin a/b immune globulin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68403-1100</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>human botulinum neurotoxin a/b immune globulin</strong> (human botulinum neurotoxin a/b immune globulin) </td>
<td class="formItem">human botulinum neurotoxin a/b immune globulin</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>albumin human</strong></td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, monobasic, anhydrous</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68403-1100-6</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125034</td>
<td class="formItem">10/23/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>CALIFORNIA DEPARTMENT OF PUBLIC HEALTH
							(004519216)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter HealthCare Corporation</td>
<td class="formItem"></td>
<td class="formItem">085206634</td>
<td class="formItem">MANUFACTURE(68403-1100)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cangene BioPharma Inc.</td>
<td class="formItem"></td>
<td class="formItem">050783398</td>
<td class="formItem">MANUFACTURE(68403-1100)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions</td>
<td class="formItem"></td>
<td class="formItem">962674474</td>
<td class="formItem">LABEL(68403-1100), PACK(68403-1100)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1e18e7a3-5890-45d1-ac79-e44ea37301aa</div>
<div>Set id: 9ec59262-35c1-4d8e-8451-a7cfbacb0675</div>
<div>Version: 8</div>
<div>Effective Time: 20141119</div>
</div>
</div> <div class="DistributorName">CALIFORNIA DEPARTMENT OF PUBLIC HEALTH</div></p>
</body></html>
